Fusion Genomics is a molecular diagnostics company developing ONETest™, an in-hospital targeted metagenomic platform designed to close diagnostic gaps in life-threatening infections.
We combine targeted metagenomics, automation, and FusionCloud™ Actionable Intelligence to help hospital laboratories turn complex microbial sequence data into clinically interpretable results.
BAL samples in the current clinical validation narrative.
Diverse samples tested globally across platform development.
Target sample-to-result workflow for hospital implementation.
Actionable Intelligence for relevance, resistance, and causation support.
Fusion Genomics develops technologies for hospital-based genomic diagnostics. Availability and use are subject to applicable laboratory validation and regulatory requirements.
Critical-care teams need answers inside the treatment window. Our mission is to make broad, sequencing-based infectious disease diagnostics practical for hospital laboratories—not only technically possible, but operationally deployable.
We focus on high-acuity infections where delayed or incomplete diagnosis can materially affect treatment decisions.
Our platform is designed around existing lab infrastructure, automation, and practical workflows for in-house testing.
FusionCloud™ moves beyond organism detection by ranking signals and supporting clinical interpretation.
Fusion Genomics was founded by scientists and engineers with deep experience translating complex genomic data into practical clinical assays. The company’s early work in genome-based diagnostics evolved into a focused mission: solve the diagnostic gap for life-threatening infections in hospitalized patients.
The company was built on the ability to convert next-generation sequencing into clinically useful molecular diagnostics.
Fusion redirected its platform toward the unresolved problem of undiagnosed infections in hospitalized and immunocompromised patients.
The result is a targeted metagenomic system combining QuantumProbes™, automation, UniPrep™, and FusionCloud™ into a hospital-oriented diagnostic workflow.
Fusion is now focused on translating validation, automation, and hospital economics into scalable LDT-first deployment across leading health systems.
Fusion owns and integrates the major elements required to make hospital metagenomics practical: enrichment chemistry, workflow automation, library preparation, and AI-driven interpretation.
Targeted capture of pathogen DNA across core-genome loci and related lineages.
Walk-away processing designed to reduce labor burden and improve reproducibility.
A sequencing-ready library workflow compatible with standard sequencing infrastructure.
Actionable Intelligence that ranks relevance, resistance, and causation support.
Fusion’s team brings together genomics, computational biology, automation, regulatory, product development, and company-building experience.
Board Chair
Serial entrepreneur with $1.4B in exits and experience scaling technology companies.
CEO / CSO
Scientist with 20+ years of research experience leading scientific strategy and deployment programs.
CTO
Engineering and IT leader with deep CAP/CLIA infrastructure and bioinformatics systems experience.
Head, Computational Biology
Computational microbiologist and co-architect of the ONETest™ platform.
VP, Regulatory Affairs
Regulatory and operations leader with senior experience in clinical and precision medicine programs.
VP, Product Development
Molecular biologist leading assay development, production, and product execution.
Fusion’s advisory and operating support network brings deep expertise in infectious disease, clinical microbiology, molecular diagnostics, oncology genomics, metagenomic bioinformatics, finance, and commercialization strategy.
Clinical Microbiology & Infectious Disease Advisor
Infectious disease physician and clinical microbiologist with 35+ years as Medical Director of the UF Health Shands Hospital Clinical Microbiology and Virology laboratories.
Molecular Diagnostics Advisor
Molecular biologist specializing in molecular diagnostics, bacterial drug resistance testing, bacterial and fungal typing, and microarray-based diagnostic development.
Co-Founder & Medical Advisor
Physician-scientist whose work in childhood cancers and adult breast tumours helped form the scientific foundation for Fusion’s early diagnostic programs.
Clinical Metagenomics & Bioinformatics Advisor
Board-certified medical microbiologist and founder of BugSeq Bioinformatics, with experience supporting sequencing analysis for clinical and public health laboratories.
Fractional Chief Financial Officer
CPA and MBA with 15+ years of senior finance and operations experience. Chanel supports Fusion’s commercialization transition through financial strategy, capital planning, cash flow management, investor readiness, and growth-stage financing.
Explore the platform or contact Fusion Genomics to discuss hospital adoption, partnerships, or investment.